{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:21:49Z","timestamp":1792045309711,"version":"4.4.0"},"reference-count":185,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:sec><jats:title\/><jats:p>Alzheimer\u2019s disease (AD) is the most common neurodegenerative disease, and is part of a massive and growing health care burden that is destroying the cognitive function of more than 50 million individuals worldwide. Today, therapeutic options are limited to approaches with mild symptomatic benefits. The failure in developing effective drugs is attributed to, but not limited to the highly heterogeneous nature of AD with multiple underlying hypotheses and multifactorial pathology. In addition, targeted drug delivery to the central nervous system (CNS), for the diagnosis and therapy of neurological diseases like AD, is restricted by the challenges posed by blood-brain interfaces surrounding the CNS, limiting the bioavailability of therapeutics. Research done over the last decade has focused on developing new strategies to overcome these limitations and successfully deliver drugs to the CNS. Nanoparticles, that are capable of encapsulating drugs with sustained drug release profiles and adjustable physiochemical properties, can cross the protective barriers surrounding the CNS. Thus, nanotechnology offers new hope for AD treatment as a strong alternative to conventional drug delivery mechanisms. In this review, the potential application of nanoparticle based approaches in Alzheimer\u2019s disease and their implications in therapy is discussed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666191118123151","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T08:10:41Z","timestamp":1574237441000},"page":"628-646","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Alzheimer\u2019s Disease Targeted Nano-Based Drug Delivery Systems"],"prefix":"10.2174","volume":"21","author":[{"given":"G\u00fclcem","family":"Altinoglu","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Engineering, Near East University, P.O. Box: 99138, North Cyprus via Mersin 10, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terin","family":"Adali","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Faculty of Engineering, Near East University, P.O. Box: 99138, North Cyprus via Mersin 10, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"Kumar A.","year":"2015","unstructured":"Kumar A.; Singh A.; Ekavali ; A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep [http:\/\/dx.doi.org\/10.1016\/j.pharep.2014.09.004]2015,67(2),195-203","journal-title":"Pharmacol Rep"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"Saraiva C.","year":"2016","unstructured":"Saraiva C.; Pra\u00e7a C.; Ferreira R.; Santos T.; Ferreira L.; Bernardino L.; Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2016.05.044].2016,235,34-47","journal-title":"J Control Release"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"Brookmeyer R.","year":"2007","unstructured":"Brookmeyer R.; Johnson E.; Ziegler-Graham K.; Arrighi H.M.; Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement [http:\/\/dx.doi.org\/10.1016\/j.jalz.2007.04.381].2007,3(3),186-191","journal-title":"Alzheimers Dement"},{"key":"ref=4","first-page":"3734","volume":"5","author":"Singh A.","year":"2014","unstructured":"Singh A.; Alzheimer\u2019s disease Inhibitors: Current status and future prospects. IJPLS 2014,5(8),3734-3740","journal-title":"IJPLS"},{"key":"ref=5","year":"2013","unstructured":"Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association2013","journal-title":"Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/440284a","volume":"440","author":"Morris R.","year":"2006","unstructured":"Morris R.; Mucke L.; Alzheimer\u2019s disease: A needle from the haystack. Nature [http:\/\/dx.doi.org\/10.1038\/440284a]2006,440(7082),284-285","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cger.2014.04.001","volume":"30","author":"Hugo J.","year":"2014","unstructured":"Hugo J.; Ganguli M.; Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med [http:\/\/dx.doi.org\/10.1016\/j.cger.2014.04.001]2014,30(3),421-442","journal-title":"Clin Geriatr Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"Kim J.","year":"2009","unstructured":"Kim J.; Basak J.M.; Holtzman D.M.; The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron [http:\/\/dx.doi.org\/10.1016\/j.neuron.2009.06.026]2009,63(3),287-303","journal-title":"Neuron"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12974-017-0835-4","volume":"14","author":"Jendresen C.","year":"2017","unstructured":"Jendresen C.; \u00c5rskog V.; Daws M.R.; Nilsson L.N.; The Alzheimer\u2019s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. J Neuroinflammation [http:\/\/dx.doi.org\/10.1186\/s12974-017-0835-4]2017,14(1),59","journal-title":"J Neuroinflammation"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/00207454.2010.551432","volume":"121","author":"Obulesu M.","year":"2011","unstructured":"Obulesu M.; Somashekhar R.; Venu R.; Genetics of Alzheimer\u2019s disease: an insight into presenilins and apolipoprotein E instigated neurodegeneration. Int J Neurosci [http:\/\/dx.doi.org\/10.3109\/00207454.2010.551432]2011,121(5),229-236","journal-title":"Int J Neurosci"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"Du X.","year":"2018","unstructured":"Du X.; Wang X.; Geng M.; Alzheimer\u2019s disease hypothesis and related therapies. Transl Neurodegener [http:\/\/dx.doi.org\/10.1186\/s40035-018-0107-y]2018,7,2","journal-title":"Transl Neurodegener"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","volume":"35","author":"Craig L.A.","year":"2011","unstructured":"Craig L.A.; Hong N.S.; McDonald R.J.; Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease. Neurosci Biobehav Rev [http:\/\/dx.doi.org\/10.1016\/j.neubiorev.2011.03.001]2011,35(6),1397-1409","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JAD-2008-15213","volume":"15","author":"Becker R.E.","year":"2008","unstructured":"Becker R.E.; Greig N.H.; Giacobini E.; Why do so many drugs for Alzheimer\u2019s disease fail in development? Time for new methods and new practices? J Alzheimers Dis [http:\/\/dx.doi.org\/10.3233\/JAD-2008-15213]2008,15(2),303-325","journal-title":"J Alzheimers Dis"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/YCO.0000000000000310","volume":"30","author":"Ansari S.A.","year":"2017","unstructured":"Ansari S.A.; Satar R.; Perveen A.; Ashraf G.M.; Current opinion in Alzheimer\u2019s disease therapy by nanotechnology-based approaches. Curr Opin Psychiatry [http:\/\/dx.doi.org\/10.1097\/YCO.0000000000000310]2017,30(2),128-135","journal-title":"Curr Opin Psychiatry"},{"key":"ref=15","first-page":"449","volume":"138","author":"Aprahamian I.","year":"2013","unstructured":"Aprahamian I.; Stella F.; Forlenza O.V.; New treatment strategies for Alzheimer\u2019s disease: is there a hope? Indian J Med Res 2013,138(4),449-460","journal-title":"Indian J Med Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"Hardy J.A.","year":"1992","unstructured":"Hardy J.A.; Higgins G.A.; Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science [http:\/\/dx.doi.org\/10.1126\/science.1566067]1992,256(5054),184-185","journal-title":"Science"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"Kametani F.","year":"2018","unstructured":"Kametani F.; Hasegawa M.; Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer\u2019s Disease. Front Neurosci [http:\/\/dx.doi.org\/10.3389\/fnins.2018.00025]2018,12,25","journal-title":"Front Neurosci"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1582-4934.2009.00609.x","volume":"13","author":"Bharadwaj P.R.","year":"2009","unstructured":"Bharadwaj P.R.; Dubey A.K.; Masters C.L.; Martins R.N.; Macreadie I.G.; Abeta aggregation and possible implications in Alzheimer\u2019s disease pathogenesis. J Cell Mol Med [http:\/\/dx.doi.org\/10.1111\/j.1582-4934.2009.00609.x]2009,13(3),412-421","journal-title":"J Cell Mol Med"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","volume":"18","author":"Musiek E.S.","year":"2015","unstructured":"Musiek E.S.; Holtzman D.M.; Three dimensions of the amyloid hypothesis: time, space and \u2018wingmen\u2019. Nat Neurosci [http:\/\/dx.doi.org\/10.1038\/nn.4018]2015,18(6),800-806","journal-title":"Nat Neurosci"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","volume":"15","author":"Ricciarelli R.","year":"2017","unstructured":"Ricciarelli R.; Fedele E.; The Amyloid Cascade Hypothesis in Alzheimer\u2019s Disease: It\u2019s Time to Change Our Mind. Curr Neuropharmacol [http:\/\/dx.doi.org\/10.2174\/1570159X15666170116143743]2017,15(6),926-935","journal-title":"Curr Neuropharmacol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","volume":"2","author":"Ch\u00e9telat G.","year":"2013","unstructured":"Ch\u00e9telat G.; La Joie R.; Villain N.; Perrotin A.; de La Sayette V.; Eustache F.; Vandenberghe R.; Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer\u2019s disease. Neuroimage Clin [http:\/\/dx.doi.org\/10.1016\/j.nicl.2013.02.006]2013,2,356-365","journal-title":"Neuroimage Clin"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/alzrt214","volume":"5","author":"Pooler A.M.","year":"2013","unstructured":"Pooler A.M.; Polydoro M.; Wegmann S.; Nicholls S.B.; Spires-Jones T.L.; Hyman B.T.; Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets. Alzheimers Res Ther [http:\/\/dx.doi.org\/10.1186\/alzrt214]2013,5(5),49","journal-title":"Alzheimers Res Ther"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"Gong C.X.","year":"2008","unstructured":"Gong C.X.; Iqbal K.; Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem [http:\/\/dx.doi.org\/10.2174\/092986708785909111]2008,15(23),2321-2328","journal-title":"Curr Med Chem"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","volume":"41","author":"Maccioni R.B.","year":"2010","unstructured":"Maccioni R.B.; Far\u00edas G.; Morales I.; Navarrete L.; The revitalized tau hypothesis on Alzheimer\u2019s disease. Arch Med Res [http:\/\/dx.doi.org\/10.1016\/j.arcmed.2010.03.007]2010,41(3),226-231","journal-title":"Arch Med Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1471-4159.2009.06511.x","volume":"112","author":"Meraz-R\u00edos M.A.","year":"2010","unstructured":"Meraz-R\u00edos M.A.; Lira-De Le\u00f3n K.I.; Campos-Pe\u00f1a V.; De Anda-Hern\u00e1ndez M.A.; Mena-L\u00f3pez R.; Tau oligomers and aggregation in Alzheimer\u2019s disease. J Neurochem [http:\/\/dx.doi.org\/10.1111\/j.1471-4159.2009.06511.x]2010,112(6),1353-1367","journal-title":"J Neurochem"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/1476830511Y.0000000028","volume":"15","author":"Albarracin S.L.","year":"2012","unstructured":"Albarracin S.L.; Stab B.; Casas Z.; Sutachan J.J.; Samudio I.; Gonzalez J.; Gonzalo L.; Capani F.; Morales L.; Barreto G.E.; Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci [http:\/\/dx.doi.org\/10.1179\/1476830511Y.0000000028]2012,15(1),1-9","journal-title":"Nutr Neurosci"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/1871527315666160202124518","volume":"15","author":"Khan T.A.","year":"2016","unstructured":"Khan T.A.; Hassan I.; Ahmad A.; Perveen A.; Aman S.; Quddusi S.; Alhazza I.M.; Ashraf G.M.; Aliev G.; Recent Updates on the Dynamic Association Between Oxidative Stress and Neurodegenerative Disorders. CNS Neurol Disord Drug Targets [http:\/\/dx.doi.org\/10.2174\/1871527315666160202124518]2016,15(3),310-320","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"Huang W.J.","year":"2016","unstructured":"Huang W.J.; Zhang X.; Chen W.W.; Role of oxidative stress in Alzheimer\u2019s disease. Biomed Rep [http:\/\/dx.doi.org\/10.3892\/br.2016.630]2016,4(5),519-522","journal-title":"Biomed Rep"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biomaterials.2013.09.063","volume":"35","author":"Zhang C.","year":"2014","unstructured":"Zhang C.; Wan X.; Zheng X.; Shao X.; Liu Q.; Zhang Q.; Qian Y.; Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer\u2019s disease mice. Biomaterials [http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2013.09.063]2014,35(1),456-465","journal-title":"Biomaterials"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"Terry A.V.","year":"2003","unstructured":"Terry A.V.; Buccafusco J.J.; The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther [http:\/\/dx.doi.org\/10.1124\/jpet.102.041616]2003,306(3),821-827","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"Colovi\u0107 M.B.","year":"2013","unstructured":"Colovi\u0107 M.B.; Krsti\u0107 D.Z.; Lazarevi\u0107-Pa\u0161ti T.D.; Bond\u017ei\u0107 A.M.; Vasi\u0107 V.M.; Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol [http:\/\/dx.doi.org\/10.2174\/1570159X11311030006]2013,11(3),315-335","journal-title":"Curr Neuropharmacol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0091-3057(78)90364-7","volume":"9","author":"Bartus R.T.","year":"1978","unstructured":"Bartus R.T.; Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav [http:\/\/dx.doi.org\/10.1016\/0091-3057(78)90364-7]1978,9(6),833-836","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1212\/WNL.27.8.783","volume":"27","author":"Drachman D.A.","year":"1977","unstructured":"Drachman D.A.; Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology [http:\/\/dx.doi.org\/10.1212\/WNL.27.8.783]1977,27(8),783-790","journal-title":"Neurology"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"Hajipour M.J.","year":"2017","unstructured":"Hajipour M.J.; Santoso M.R.; Rezaee F.; Aghaverdi H.; Mahmoudi M.; Perry G.; Advances in Alzheimer\u2019s Diagnosis and Therapy: The Implications of Nanotechnology. Trends Biotechnol [http:\/\/dx.doi.org\/10.1016\/j.tibtech.2017.06.002]2017,35(10),937-953","journal-title":"Trends Biotechnol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","volume":"43","author":"Md S.","year":"2018","unstructured":"Md S.; Bhattmisra S.K.; Zeeshan F.; Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. J Drug Deliv Sci Technol [http:\/\/dx.doi.org\/10.1016\/j.jddst.2017.09.022].2018,43,295-310","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nano.2011.03.008","volume":"7","author":"Brambilla D.","year":"2011","unstructured":"Brambilla D.; Le Droumaguet B.; Nicolas J.; Hashemi S.H.; Wu L.P.; Moghimi S.M.; Couvreur P.; Andrieux K.; Nanotechnologies for Alzheimer\u2019s disease: diagnosis, therapy, and safety issues. Nanomedicine (Lond) [http:\/\/dx.doi.org\/10.1016\/j.nano.2011.03.008]2011,7(5),521-540","journal-title":"Nanomedicine (Lond)"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2174\/1567205014666170203125008","volume":"14","author":"Leszek J.","year":"2017","unstructured":"Leszek J.; Md Ashraf G.; Tse W.H.; Zhang J.; Gasiorowski K.; Avila-Rodriguez M.F.; Tarasov V.V.; Barreto G.E.; Klochkov S.G.; Bachurin S.O.; Aliev G.; Nanotechnology for Alzheimer Disease. Curr Alzheimer Res [http:\/\/dx.doi.org\/10.2174\/1567205014666170203125008]2017,14(11),1182-1189","journal-title":"Curr Alzheimer Res"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","volume":"12","author":"Pardridge W.M.","year":"2007","unstructured":"Pardridge W.M.; Blood-brain barrier delivery. Drug Discov Today [http:\/\/dx.doi.org\/10.1016\/j.drudis.2006.10.013]2007,12(1-2),54-61","journal-title":"Drug Discov Today"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2010.11.033","volume":"152","author":"Sahni J.K.","year":"2011","unstructured":"Sahni J.K.; Doggui S.; Ali J.; Baboota S.; Dao L.; Ramassamy C.; Neurotherapeutic applications of nanoparticles in Alzheimer\u2019s disease. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2010.11.033]2011,152(2),208-231","journal-title":"J Control Release"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3109\/03639045.2015.1052081","volume":"41","author":"Md S.","year":"2015","unstructured":"Md S.; Mustafa G.; Baboota S.; Ali J.; Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug Dev Ind Pharm [http:\/\/dx.doi.org\/10.3109\/03639045.2015.1052081]2015,41(12),1922-1934","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.peptides.2015.03.010","volume":"72","author":"Banks W.A.","year":"2015","unstructured":"Banks W.A.; Peptides and the blood-brain barrier. Peptides [http:\/\/dx.doi.org\/10.1016\/j.peptides.2015.03.010]2015,72,16-19","journal-title":"Peptides"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"Engelhardt B.","year":"2009","unstructured":"Engelhardt B.; Sorokin L.; The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol [http:\/\/dx.doi.org\/10.1007\/s00281-009-0177-0]2009,31(4),497-511","journal-title":"Semin Immunopathol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","volume":"6","author":"Gao H.","year":"2016","unstructured":"Gao H.; Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B [http:\/\/dx.doi.org\/10.1016\/j.apsb.2016.05.013]2016,6(4),268-286","journal-title":"Acta Pharm Sin B"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3109\/13550289909021285","volume":"5","author":"Pardridge W.M.","year":"1999","unstructured":"Pardridge W.M.; Blood-brain barrier biology and methodology. J Neurovirol [http:\/\/dx.doi.org\/10.3109\/13550289909021285]1999,5(6),556-569","journal-title":"J Neurovirol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1389200043489126","volume":"5","author":"Graff C.L.","year":"2004","unstructured":"Graff C.L.; Pollack G.M.; Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab [http:\/\/dx.doi.org\/10.2174\/1389200043489126]2004,5(1),95-108","journal-title":"Curr Drug Metab"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/1061186X.2011.607499","volume":"20","author":"Fazil M.","year":"2012","unstructured":"Fazil M.; Shadab ; Baboota S.; Sahni J.K.; Ali J.; Nanotherapeutics for Alzheimer\u2019s disease (AD): Past, present and future. J Drug Target [http:\/\/dx.doi.org\/10.3109\/1061186X.2011.607499]2012,20(2),97-113","journal-title":"J Drug Target"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/jps.2600651217","volume":"65","author":"Birrenbach G.","year":"1976","unstructured":"Birrenbach G.; Speiser P.P.; Polymerized micelles and their use as adjuvants in immunology. J Pharm Sci [http:\/\/dx.doi.org\/10.1002\/jps.2600651217]1976,65(12),1763-1766","journal-title":"J Pharm Sci"},{"key":"ref=48","author":"Khan I.","year":"2017","unstructured":"Khan I.; Saeed K.; Khan I.; Nanoparticles: Properties, applications and toxicities. Arab J Chem 2017","journal-title":"Arab J Chem"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/molecules22020277","volume":"22","author":"Loureiro J.A.","year":"2017","unstructured":"Loureiro J.A.; Andrade S.; Duarte A.; Neves A.R.; Queiroz J.F.; Nunes C.; Sevin E.; Fenart L.; Gosselet F.; Coelho M.A.; Pereira M.C.; Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer\u2019s Disease. Molecules [http:\/\/dx.doi.org\/10.3390\/molecules22020277]2017,22(2),277","journal-title":"Molecules"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","volume":"245","author":"Wen M.M.","year":"2017","unstructured":"Wen M.M.; El-Salamouni N.S.; El-Refaie W.M.; Hazzah H.A.; Ali M.M.; Tosi G.; Farid R.M.; Blanco-Prieto M.J.; Billa N.; Hanafy A.S.; Nanotechnology-based drug delivery systems for Alzheimer\u2019s disease management: Technical, industrial, and clinical challenges. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2016.11.025]2017,245,95-107","journal-title":"J Control Release"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/nn501292z","volume":"8","author":"Goldsmith M.","year":"2014","unstructured":"Goldsmith M.; Abramovitz L.; Peer D.; Precision nanomedicine in neurodegenerative diseases. ACS Nano [http:\/\/dx.doi.org\/10.1021\/nn501292z]2014,8(3),1958-1965","journal-title":"ACS Nano"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/17425240902939143","volume":"6","author":"Barbu E.","year":"2009","unstructured":"Barbu E.; Moln\u00e0r E.; Tsibouklis J.; G\u00f3recki D.C.; The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv [http:\/\/dx.doi.org\/10.1517\/17425240902939143]2009,6(6),553-565","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","volume":"28","author":"Lockman P.R.","year":"2002","unstructured":"Lockman P.R.; Mumper R.J.; Khan M.A.; Allen D.D.; Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm [http:\/\/dx.doi.org\/10.1081\/DDC-120001481]2002,28(1),1-13","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.nano.2011.04.004","volume":"7","author":"Etame A.B.","year":"2011","unstructured":"Etame A.B.; Smith C.A.; Chan W.C.; Rutka J.T.; Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine (Lond) [http:\/\/dx.doi.org\/10.1016\/j.nano.2011.04.004]2011,7(6),992-1000","journal-title":"Nanomedicine (Lond)"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/ijms15021812","volume":"15","author":"Hanada S.","year":"2014","unstructured":"Hanada S.; Fujioka K.; Inoue Y.; Kanaya F.; Manome Y.; Yamamoto K.; Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles\u2019 brain permeability in association with particle size and surface modification. Int J Mol Sci [http:\/\/dx.doi.org\/10.3390\/ijms15021812]2014,15(2),1812-1825","journal-title":"Int J Mol Sci"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","volume":"66","author":"Sonavane G.","year":"2008","unstructured":"Sonavane G.; Tomoda K.; Makino K.; Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces [http:\/\/dx.doi.org\/10.1016\/j.colsurfb.2008.07.004]2008,66(2),274-280","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jconrel.2009.10.014","volume":"141","author":"Decuzzi P.","year":"2010","unstructured":"Decuzzi P.; Godin B.; Tanaka T.; Lee S.Y.; Chiappini C.; Liu X.; Ferrari M.; Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2009.10.014]2010,141(3),320-327","journal-title":"J Control Release"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(02)00267-3","volume":"243","author":"Banerjee T.","year":"2002","unstructured":"Banerjee T.; Mitra S.; Kumar Singh A.; Kumar Sharma R.; Maitra A.; Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/S0378-5173(02)00267-3]2002,243(1-2),93-105","journal-title":"Int J Pharm"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","volume":"86","author":"Singh R.","year":"2009","unstructured":"Singh R.; Lillard J.W.; Nanoparticle-based targeted drug delivery. Exp Mol Pathol [http:\/\/dx.doi.org\/10.1016\/j.yexmp.2008.12.004]2009,86(3),215-223","journal-title":"Exp Mol Pathol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0168-3659(00)00367-9","volume":"70","author":"Redhead H.M.","year":"2001","unstructured":"Redhead H.M.; Davis S.S.; Illum L.; Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release [http:\/\/dx.doi.org\/10.1016\/S0168-3659(00)00367-9]2001,70(3),353-363","journal-title":"J Control Release"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-12-391860-4.00002-1","volume":"508","author":"Pan H.","year":"2012","unstructured":"Pan H.; Marsh J.N.; Christenson E.T.; Soman N.R.; Ivashyna O.; Lanza G.M.; Schlesinger P.H.; Wickline S.A.; Postformulation peptide drug loading of nanostructures. Methods Enzymol [http:\/\/dx.doi.org\/10.1016\/B978-0-12-391860-4.00002-1].2012,508,17-39","journal-title":"Methods Enzymol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","volume":"6","author":"Hans M.L.","year":"2002","unstructured":"Hans M.L.; Lowman A.M.; Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid St M [http:\/\/dx.doi.org\/10.1016\/S1359-0286(02)00117-1].2002,6(4),319-327","journal-title":"Curr Opin Solid St M"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1021\/nn5018523","volume":"8","author":"Bramini M.","year":"2014","unstructured":"Bramini M.; Ye D.; Hallerbach A.; Nic Raghnaill M.; Salvati A.; Aberg C.; Dawson K.A.; Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano [http:\/\/dx.doi.org\/10.1021\/nn5018523]2014,8(5),4304-4312","journal-title":"ACS Nano"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1073\/pnas.0914140107","volume":"107","author":"Choi C.H.J.","year":"2010","unstructured":"Choi C.H.J.; Alabi C.A.; Webster P.; Davis M.E.; Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA [http:\/\/dx.doi.org\/10.1073\/pnas.0914140107]2010,107(3),1235-1240","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","volume":"110","author":"Wiley D.T.","year":"2013","unstructured":"Wiley D.T.; Webster P.; Gale A.; Davis M.E.; Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA [http:\/\/dx.doi.org\/10.1073\/pnas.1307152110]2013,110(21),8662-8667","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2007.06.023","volume":"344","author":"Jallouli Y.","year":"2007","unstructured":"Jallouli Y.; Paillard A.; Chang J.; Sevin E.; Betbeder D.; Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2007.06.023]2007,344(1-2),103-109","journal-title":"Int J Pharm"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1021\/nn5003375","volume":"8","author":"Gao X.","year":"2014","unstructured":"Gao X.; Qian J.; Zheng S.; Changyi Y.; Zhang J.; Ju S.; Zhu J.; Li C.; Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist. ACS Nano [http:\/\/dx.doi.org\/10.1021\/nn5003375]2014,8(4),3678-3689","journal-title":"ACS Nano"},{"key":"ref=68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024374","volume":"6","author":"Arvizo R.R.","year":"2011","unstructured":"Arvizo R.R.; Miranda O.R.; Moyano D.F.; Walden C.A.; Giri K.; Bhattacharya R.; Robertson J.D.; Rotello V.M.; Reid J.M.; Mukherjee P.; Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One [http:\/\/dx.doi.org\/10.1371\/journal.pone.0024374]2011,6(9)","journal-title":"PLoS One"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4155\/tde.12.84","volume":"3","author":"Doggui S.","year":"2012","unstructured":"Doggui S.; Dao L.; Ramassamy C.; Potential of drug-loaded nanoparticles for Alzheimer\u2019s disease: diagnosis, prevention and treatment. Ther Deliv [http:\/\/dx.doi.org\/10.4155\/tde.12.84]2012,3(9),1025-1027","journal-title":"Ther Deliv"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pneurobio.2014.05.002","volume":"119-120","author":"Cupaioli F.A.","year":"2014","unstructured":"Cupaioli F.A.; Zucca F.A.; Boraschi D.; Zecca L.; Engineered nanoparticles. How brain friendly is this new guest? Prog Neurobiol [http:\/\/dx.doi.org\/10.1016\/j.pneurobio.2014.05.002]2014,119-120,20-38","journal-title":"Prog Neurobiol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2012.12.013","volume":"166","author":"Naahidi S.","year":"2013","unstructured":"Naahidi S.; Jafari M.; Edalat F.; Raymond K.; Khademhosseini A.; Chen P.; Biocompatibility of engineered nanoparticles for drug delivery. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2012.12.013]2013,166(2),182-194","journal-title":"J Control Release"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"13761","DOI":"10.1523\/JNEUROSCI.4246-09.2009","volume":"29","author":"Karatas H.","year":"2009","unstructured":"Karatas H.; Aktas Y.; Gursoy-Ozdemir Y.; Bodur E.; Yemisci M.; Caban S.; Vural A.; Pinarbasli O.; Capan Y.; Fernandez-Megia E.; Novoa-Carballal R.; Riguera R.; Andrieux K.; Couvreur P.; Dalkara T.; A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci [http:\/\/dx.doi.org\/10.1523\/JNEUROSCI.4246-09.2009]2009,29(44),13761-13769","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrd4503","volume":"14","author":"Cheng C.J.","year":"2015","unstructured":"Cheng C.J.; Tietjen G.T.; Saucier-Sawyer J.K.; Saltzman W.M.; A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov [http:\/\/dx.doi.org\/10.1038\/nrd4503]2015,14(4),239-247","journal-title":"Nat Rev Drug Discov"},{"key":"ref=74","author":"Silva A.C.","unstructured":"Silva A.C.; Santos D.; Ferreira D.; Souto E.B.; Nalwa H.S.; In: Encyclopedia of Nanoscience and Nanotechnology; H.S Nalwa, Ed. American: Scientific. 2011; pp. 1-14"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","volume":"87","author":"Gastaldi L.","year":"2014","unstructured":"Gastaldi L.; Battaglia L.; Peira E.; Chirio D.; Muntoni E.; Solazzi I.; Gallarate M.; Dosio F.; Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2014.05.004]2014,87(3),433-444","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nano.2009.04.008","volume":"6","author":"Mishra B.","year":"2010","unstructured":"Mishra B.; Patel B.B.; Tiwari S.; Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine (Lond) [http:\/\/dx.doi.org\/10.1016\/j.nano.2009.04.008]2010,6(1),9-24","journal-title":"Nanomedicine (Lond)"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","volume":"127","author":"Kaur I.P.","year":"2008","unstructured":"Kaur I.P.; Bhandari R.; Bhandari S.; Kakkar V.; Potential of solid lipid nanoparticles in brain targeting. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2007.12.018]2008,127(2),97-109","journal-title":"J Control Release"},{"key":"ref=78","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/26\/49\/495103","volume":"26","author":"Neves A.R.","year":"2015","unstructured":"Neves A.R.; Queiroz J.F.; Weksler B.; Romero I.A.; Couraud P.O.; Reis S.; Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E. Nanotechnology [http:\/\/dx.doi.org\/10.1088\/0957-4484\/26\/49\/495103]2015,26(49)","journal-title":"Nanotechnology"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3934\/molsci.2015.3.332","volume":"2","author":"Robinson M.","year":"2015","unstructured":"Robinson M.; Lee B.Y.; Leonenko Z.; Drugs and drug delivery systems targeting amyloid- \u03b2 in Alzheimer\u2019s disease. AIMS Mol Sci [http:\/\/dx.doi.org\/10.3934\/molsci.2015.3.332].2015,2(3),332-358","journal-title":"AIMS Mol Sci"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/187221013804484827","volume":"7","author":"Fang C.L.","year":"2013","unstructured":"Fang C.L.; Al-Suwayeh S.A.; Fang J.Y.; Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol [http:\/\/dx.doi.org\/10.2174\/187221013804484827]2013,7(1),41-55","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fbioe.2016.00049","volume":"4","author":"Hadavi D.","year":"2016","unstructured":"Hadavi D.; Poot A.A.; Biomaterials for the treatment of Alzheimer\u2019s disease. Front Bioeng Biotechnol [http:\/\/dx.doi.org\/10.3389\/fbioe.2016.00049]2016,4,49","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","volume":"269","author":"Kaur I.P.","year":"2004","unstructured":"Kaur I.P.; Garg A.; Singla A.K.; Aggarwal D.; Vesicular systems in ocular drug delivery: an overview. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2003.09.016]2004,269(1),1-14","journal-title":"Int J Pharm"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(98)00006-4","volume":"165","author":"Gulati M.","year":"1998","unstructured":"Gulati M.; Grover M.; Singh S.; Singh M.; Lipophilic drug derivatives in liposomes. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/S0378-5173(98)00006-4].1998,165(2),129-168","journal-title":"Int J Pharm"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.2147\/IJN.S87148","volume":"10","author":"Fonseca-Santos B.","year":"2015","unstructured":"Fonseca-Santos B.; Gremi\u00e3o M.P.; Chorilli M.; Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S87148]2015,10,4981-5003","journal-title":"Int J Nanomedicine"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.phrs.2010.02.004","volume":"62","author":"Fernandes C.","year":"2010","unstructured":"Fernandes C.; Soni U.; Patravale V.; Nano-interventions for neurodegenerative disorders. Pharmacol Res [http:\/\/dx.doi.org\/10.1016\/j.phrs.2010.02.004]2010,62(2),166-178","journal-title":"Pharmacol Res"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.2174\/138161281941131219123329","volume":"19","author":"Silva A.C.","year":"2013","unstructured":"Silva A.C.; Gonz\u00e1lez-Mira E.; Lobo J.M.; Amaral M.H.; Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer\u2019s and schizophrenia. Curr Pharm Des [http:\/\/dx.doi.org\/10.2174\/138161281941131219123329]2013,19(41),7185-7195","journal-title":"Curr Pharm Des"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-12-811838-2.00013-8","author":"Pathak K.","year":"2018","unstructured":"Pathak K.; Pattnaik S.; Swain K.; Nanoemulsions; SM Jafari [http:\/\/dx.doi.org\/10.1016\/B978-0-12-811838-2.00013-8]2018,415-433","journal-title":"Nanoemulsions; SM Jafari"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2125.2011.04134.x","volume":"73","author":"Salomone S.","year":"2012","unstructured":"Salomone S.; Caraci F.; Leggio G.M.; Fedotova J.; Drago F.; New pharmacological strategies for treatment of Alzheimer\u2019s disease: focus on disease modifying drugs. Br J Clin Pharmacol [http:\/\/dx.doi.org\/10.1111\/j.1365-2125.2011.04134.x]2012,73(4),504-517","journal-title":"Br J Clin Pharmacol"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2008.12.003","volume":"5","author":"Cummings J.L.","year":"2009","unstructured":"Cummings J.L.; Defining and labeling disease-modifying treatments for Alzheimer\u2019s disease. Alzheimers Dement [http:\/\/dx.doi.org\/10.1016\/j.jalz.2008.12.003]2009,5(5),406-418","journal-title":"Alzheimers Dement"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JAD-2008-13210","volume":"13","author":"Nazem A.","year":"2008","unstructured":"Nazem A.; Mansoori G.A.; Nanotechnology solutions for Alzheimer\u2019s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis [http:\/\/dx.doi.org\/10.3233\/JAD-2008-13210]2008,13(2),199-223","journal-title":"J Alzheimers Dis"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1208\/s12249-009-9279-1","volume":"10","author":"Songjiang Z.","year":"2009","unstructured":"Songjiang Z.; Lixiang W.; Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech [http:\/\/dx.doi.org\/10.1208\/s12249-009-9279-1]2009,10(3),900-905","journal-title":"AAPS PharmSciTech"},{"key":"ref=92","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9040053","volume":"9","author":"Mohammed M.A.","year":"2017","unstructured":"Mohammed M.A.; Syeda J.T.M.; Wasan K.M.; Wasan E.K.; An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics [http:\/\/dx.doi.org\/10.3390\/pharmaceutics9040053]2017,9(4)","journal-title":"Pharmaceutics"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1096\/fj.01-0841fje","volume":"16","author":"Permanne B.","year":"2002","unstructured":"Permanne B.; Adessi C.; Saborio G.P.; Fraga S.; Frossard M.J.; Van Dorpe J.; Dewachter I.; Banks W.A.; Van Leuven F.; Soto C.; Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer\u2019s disease by treatment with a beta-sheet breaker peptide. FASEB J [http:\/\/dx.doi.org\/10.1096\/fj.01-0841fje]2002,16(8),860-862","journal-title":"FASEB J"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","volume":"145","author":"Loureiro J.A.","year":"2016","unstructured":"Loureiro J.A.; Gomes B.; Fricker G.; Coelho M.A.N.; Rocha S.; Pereira M.C.; Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer\u2019s disease treatment. Colloids Surf B Biointerfaces [http:\/\/dx.doi.org\/10.1016\/j.colsurfb.2016.04.041]2016,145,8-13","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","volume":"21","author":"Bala I.","year":"2004","unstructured":"Bala I.; Hariharan S.; Kumar M.N.; PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst [http:\/\/dx.doi.org\/10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20]2004,21(5),387-422","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000198339","volume":"19","author":"Fahrenkrug J.","year":"1979","unstructured":"Fahrenkrug J.; Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. Digestion [http:\/\/dx.doi.org\/10.1159\/000198339]1979,19(3),149-169","journal-title":"Digestion"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1998.tb11180.x","volume":"865","author":"Brenneman D.E.","year":"1998","unstructured":"Brenneman D.E.; Glazner G.; Hill J.M.; Hauser J.; Davidson A.; Gozes I.; VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. Ann N Y Acad Sci [http:\/\/dx.doi.org\/10.1111\/j.1749-6632.1998.tb11180.x]1998,865,207-212","journal-title":"Ann N Y Acad Sci"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1385\/JMN:20:3:315","volume":"20","author":"Gozes I.","year":"2003","unstructured":"Gozes I.; Divinsky I.; Pilzer I.; Fridkin M.; Brenneman D.E.; Spier A.D.; From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci [http:\/\/dx.doi.org\/10.1385\/JMN:20:3:315]2003,20(3),315-322","journal-title":"J Mol Neurosci"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","volume":"121","author":"Gao X.","year":"2007","unstructured":"Gao X.; Wu B.; Zhang Q.; Chen J.; Zhu J.; Zhang W.; Rong Z.; Chen H.; Jiang X.; Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2007.05.026]2007,121(3),156-167","journal-title":"J Control Release"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/157341309789378014","volume":"5","author":"Kanwar J.R.","year":"2009","unstructured":"Kanwar J.R.; Kanwar R.K.; Mahidhara G.; Recent Advances in Nanoneurology for Drug Delivery to the Brain. Curr Nanosci [http:\/\/dx.doi.org\/10.2174\/157341309789378014].2009,5(4),441-447","journal-title":"Curr Nanosci"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.31887\/DCNS.2002.4.2\/drubinow","volume":"4","author":"Rubinow D.R.","year":"2002","unstructured":"Rubinow D.R.; Schmidt P.J.; Gonadal steroids, brain, and behavior: role of context. Dialogues Clin Neurosci 2002,4(2),123-137","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.neuroscience.2010.05.031","volume":"169","author":"Amtul Z.","year":"2010","unstructured":"Amtul Z.; Wang L.; Westaway D.; Rozmahel R.F.; Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer\u2019s disease. Neuroscience [http:\/\/dx.doi.org\/10.1016\/j.neuroscience.2010.05.031]2010,169(2),781-786","journal-title":"Neuroscience"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejpb.2008.07.005","volume":"70","author":"Wang X.","year":"2008","unstructured":"Wang X.; Chi N.; Tang X.; Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2008.07.005]2008,70(3),735-740","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.01.016","volume":"119","author":"Mittal G.","year":"2007","unstructured":"Mittal G.; Sahana D.K.; Bhardwaj V.; Ravi Kumar M.N.; Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2007.01.016]2007,119(1),77-85","journal-title":"J Control Release"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","volume":"150","author":"Mittal G.","year":"2011","unstructured":"Mittal G.; Carswell H.; Brett R.; Currie S.; Kumar M.N.; Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology. J Control Release [http:\/\/dx.doi.org\/10.1016\/j.jconrel.2010.11.013]2011,150(2),220-228","journal-title":"J Control Release"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsnano.7b07625","volume":"12","author":"Chen Q.","year":"2018","unstructured":"Chen Q.; Du Y.; Zhang K.; Liang Z.; Li J.; Yu H.; Ren R.; Feng J.; Jin Z.; Li F.; Sun J.; Zhou M.; He Q.; Sun X.; Zhang H.; Tian M.; Ling D.; Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer\u2019s Disease. ACS Nano [http:\/\/dx.doi.org\/10.1021\/acsnano.7b07625]2018,12(2),1321-1338","journal-title":"ACS Nano"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","volume":"25","author":"Karthivashan G.","year":"2018","unstructured":"Karthivashan G.; Ganesan P.; Park S.Y.; Kim J.S.; Choi D.K.; Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease. Drug Deliv [http:\/\/dx.doi.org\/10.1080\/10717544.2018.1428243]2018,25(1),307-320","journal-title":"Drug Deliv"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1567201810666131113102037","volume":"11","author":"Jinwal U.K.","year":"2014","unstructured":"Jinwal U.K.; Groshev A.; Zhang J.; Grover A.; Sutariya V.B.; Preparation and characterization of methylene blue nanoparticles for Alzheimer\u2019s disease and other tauopathies. Curr Drug Deliv [http:\/\/dx.doi.org\/10.2174\/1567201810666131113102037]2014,11(4),541-550","journal-title":"Curr Drug Deliv"},{"key":"ref=109","volume":"2014","author":"Lu R.C.","year":"2014","unstructured":"Lu R.C.; Tan M.S.; Wang H.; Xie A.M.; Yu J.T.; Tan L.; Heat shock protein 70 in Alzheimer\u2019s disease. BioMed Res Int [http:\/\/dx.doi.org\/10.1155\/2014\/435203]2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=110","first-page":"538","volume":"56","author":"Koya K.","year":"1996","unstructured":"Koya K.; Li Y.; Wang H.; Ukai T.; Tatsuta N.; Kawakami M.; Shishido ; Chen L.B.; MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 1996,56(3),538-543","journal-title":"Cancer Res"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/2211738503666150328001726","volume":"2","author":"Jinwal U.K.","year":"2014","unstructured":"Jinwal U.K.; Grover A.; Narayan M.; Hirani A.; Sutariya V.; Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer\u2019s Disease and Other Tauopathies. Pharm Nanotechnol [http:\/\/dx.doi.org\/10.2174\/2211738503666150328001726]2014,2(4),217-226","journal-title":"Pharm Nanotechnol"},{"key":"ref=112","doi-asserted-by":"crossref","DOI":"10.1177\/1178646918776658","volume":"11","author":"Fricker R.A.","year":"2018","unstructured":"Fricker R.A.; Green E.L.; Jenkins S.I.; Griffin S.M.; The Influence of Nicotinamide on Health and Disease in the Central Nervous System. Int J Tryptophan Res [http:\/\/dx.doi.org\/10.1177\/1178646918776658]2018,11","journal-title":"Int J Tryptophan Res"},{"key":"ref=113","author":"Fillit H.","year":"2017","unstructured":"Fillit H.; Friedman L.; Hara Y.; Koemeter-Cox A.; McKeehan N.; Closing in on a cure - 2017 Alzheimer\u2019s clinical trials report 2017","journal-title":"Closing in on a cure - 2017 Alzheimer\u2019s clinical trials report"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40199-018-0221-5","volume":"26","author":"Vakilinezhad M.A.","year":"2018","unstructured":"Vakilinezhad M.A.; Amini A.; Akbari Javar H.; Baha\u2019addini Beigi Zarandi B.F.; Montaseri H.; Dinarvand R.; Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer\u2019s disease animal model by reducing Tau hyperphosphorylation. Daru [http:\/\/dx.doi.org\/10.1007\/s40199-018-0221-5]2018,26(2),165-177","journal-title":"Daru"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","volume":"10","author":"Francis P.T.","year":"2005","unstructured":"Francis P.T.; The interplay of neurotransmitters in Alzheimer\u2019s disease. CNS Spectr [http:\/\/dx.doi.org\/10.1017\/S1092852900014164]2005,10(11)(Suppl. 18),6-9","journal-title":"CNS Spectr"},{"key":"ref=116","first-page":"1164","volume":"14","author":"Ahmad J.","year":"2017","unstructured":"Ahmad J.; Akhter S.; Rizwanullah M.; Khan M.A.; Pigeon L.; Addo R.T.; Greig N.H.; Midoux P.; Pichon C.; Kamal M.A.; Nanotechnology Based Theranostic Approaches in Alzheimer\u2019s Disease Management: Current Status and Future Perspective. Curr Alzheimer Res [http:\/\/dx.doi.org\/10.2174\/1567205014666170508121031]2017,14(11),1164-1181","journal-title":"Curr Alzheimer Res"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Paramakrishnan N.; Suresh B.; Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res [http:\/\/dx.doi.org\/10.1016\/j.brainres.2008.01.039]2008,1200,159-168","journal-title":"Brain Res"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","volume":"76","author":"Joshi S.A.","year":"2010","unstructured":"Joshi S.A.; Chavhan S.S.; Sawant K.K.; Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2010.07.007]2010,76(2),189-199","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","volume":"41","author":"Hanafy A.S.","year":"2015","unstructured":"Hanafy A.S.; Farid R.M.; ElGamal S.S.; Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer\u2019s disease management: preparation and detection in rat brain. Drug Dev Ind Pharm [http:\/\/dx.doi.org\/10.3109\/03639045.2015.1062897]2015,41(12),2055-2068","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","volume":"47","author":"Fazil M.","year":"2012","unstructured":"Fazil M.; Md S.; Haque S.; Kumar M.; Baboota S.; Sahni J.K.; Ali J.; Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci [http:\/\/dx.doi.org\/10.1016\/j.ejps.2012.04.013]2012,47(1),6-15","journal-title":"Eur J Pharm Sci"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1166\/sam.2014.1761","volume":"6","author":"Bhavna Shadab M.","year":"2014","unstructured":"Bhavna Shadab M.; Ali M.; Bhatnagar A.; Baboota S.; Sahni J.K.; Ali J.; Design, Development, optimization and characterization of donepezil loaded chitosan nanoparticles for brain targeting to treat Alzheimer\u2019s disease. Sci Adv Mater [http:\/\/dx.doi.org\/10.1166\/sam.2014.1761]2014,6(4),720-735","journal-title":"Sci Adv Mater"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.2147\/IJN.S35329","volume":"7","author":"Alam S.","year":"2012","unstructured":"Alam S.; Khan Z.I.; Mustafa G.; Kumar M.; Islam F.; Bhatnagar A.; Ahmad F.J.; Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S35329]2012,7,5705-5718","journal-title":"Int J Nanomedicine"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","volume":"17","author":"Tumiatti V.","year":"2010","unstructured":"Tumiatti V.; Minarini A.; Bolognesi M.L.; Milelli A.; Rosini M.; Melchiorre C.; Tacrine derivatives and Alzheimer\u2019s disease. Curr Med Chem [http:\/\/dx.doi.org\/10.2174\/092986710791111206]2010,17(17),1825-1838","journal-title":"Curr Med Chem"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","volume":"70","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Paramakrishnan N.; Suresh B.; Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2008.03.009]2008,70(1),75-84","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","volume":"6","author":"Wilson B.","year":"2010","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Ramasamy M.; Suresh B.; Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine (Lond) [http:\/\/dx.doi.org\/10.1016\/j.nano.2009.04.001]2010,6(1),144-152","journal-title":"Nanomedicine (Lond)"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.biomaterials.2003.09.087","volume":"25","author":"Sun W.","year":"2004","unstructured":"Sun W.; Xie C.; Wang H.; Hu Y.; Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials [http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2003.09.087]2004,25(15),3065-3071","journal-title":"Biomaterials"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1567201815666181004094707","volume":"16","author":"Sunena","year":"2019","unstructured":"Sunena ; Singh S.K.; Mishra D.N.; Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Curr Drug Deliv [http:\/\/dx.doi.org\/10.2174\/1567201815666181004094707]2019,16(1),51-58","journal-title":"Curr Drug Deliv"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1166\/jbn.2018.2649","volume":"14","author":"Fan L.","year":"2018","unstructured":"Fan L.; Wang J.; Meng F.; Luo Y.; Sui X.; Zhao B.; Li W.; Quan D.; Yang J.; Wang Y.; Delivering the Acetylcholine Neurotransmitter by Nanodrugs as an Effective Treatment for Alzheimer\u2019s Disease. J Biomed Nanotechnol [http:\/\/dx.doi.org\/10.1166\/jbn.2018.2649]2018,14(12),2066-2076","journal-title":"J Biomed Nanotechnol"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s11064-012-0754-9","volume":"37","author":"Huang H.C.","year":"2012","unstructured":"Huang H.C.; Chang P.; Dai X.L.; Jiang Z.F.; Protective effects of curcumin on amyloid-\u03b2-induced neuronal oxidative damage. Neurochem Res [http:\/\/dx.doi.org\/10.1007\/s11064-012-0754-9]2012,37(7),1584-1597","journal-title":"Neurochem Res"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1021\/jp3034209","volume":"116","author":"Zhao L.N.","year":"2012","unstructured":"Zhao L.N.; Chiu S.W.; Benoit J.; Chew L.Y.; Mu Y.; The effect of curcumin on the stability of A\u03b2 dimers. J Phys Chem B [http:\/\/dx.doi.org\/10.1021\/jp3034209]2012,116(25),7428-7435","journal-title":"J Phys Chem B"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3233\/JAD-2004-6403","volume":"6","author":"Baum L.","year":"2004","unstructured":"Baum L.; Ng A.; Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer\u2019s disease animal models. J Alzheimers Dis [http:\/\/dx.doi.org\/10.3233\/JAD-2004-6403]2004,6(4),367-377","journal-title":"J Alzheimers Dis"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinorgbio.2003.10.014","volume":"98","author":"Daniel S.","year":"2004","unstructured":"Daniel S.; Limson J.L.; Dairam A.; Watkins G.M.; Daya S.; Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead-induced tissue damage in rat brain. J Inorg Biochem [http:\/\/dx.doi.org\/10.1016\/j.jinorgbio.2003.10.014]2004,98(2),266-275","journal-title":"J Inorg Biochem"},{"key":"ref=133","first-page":"299","volume":"9","author":"Sood S.","year":"2013","unstructured":"Sood S.; Jain K.; Gowthamarajan K.; Curcumin-donepezil\u2013loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer\u2019s disease model. Alzheimers Dement [http:\/\/dx.doi.org\/10.1016\/j.jalz.2013.05.609]2013,9(4),299","journal-title":"Alzheimers Dement"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejpb.2013.02.005","volume":"85","author":"Kakkar V.","year":"2013","unstructured":"Kakkar V.; Muppu S.K.; Chopra K.; Kaur I.P.; Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2013.02.005]2013,85(3 Pt A),339-345","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s11051-010-9907-4","volume":"12","author":"Sun M.","year":"2010","unstructured":"Sun M.; Gao Y.; Guo C.; Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res [http:\/\/dx.doi.org\/10.1007\/s11051-010-9907-4]2010,12(8),3111-3122","journal-title":"J Nanopart Res"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejps.2009.03.009","volume":"37","author":"Mulik R.","year":"2009","unstructured":"Mulik R.; Mahadik K.; Paradkar A.; Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci [http:\/\/dx.doi.org\/10.1016\/j.ejps.2009.03.009]2009,37(3-4),395-404","journal-title":"Eur J Pharm Sci"},{"key":"ref=137","first-page":"331","volume":"3","author":"Markus M.A.","year":"2008","unstructured":"Markus M.A.; Morris B.J.; Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 2008,3(2),331-339","journal-title":"Clin Interv Aging"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-9120(96)00155-5","volume":"30","author":"Soleas G.J.","year":"1997","unstructured":"Soleas G.J.; Diamandis E.P.; Goldberg D.M.; Resveratrol: a molecule whose time has come? And gone? Clin Biochem [http:\/\/dx.doi.org\/10.1016\/S0009-9120(96)00155-5]1997,30(2),91-113","journal-title":"Clin Biochem"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0891-5849(03)00062-5","volume":"34","author":"Jang J.H.","year":"2003","unstructured":"Jang J.H.; Surh Y.J.; Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med [http:\/\/dx.doi.org\/10.1016\/S0891-5849(03)00062-5]2003,34(8),1100-1110","journal-title":"Free Radic Biol Med"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1166\/jbn.2010.1161","volume":"6","author":"Frozza R.L.","year":"2010","unstructured":"Frozza R.L.; Bernardi A.; Paese K.; Hoppe J.B.; da Silva T.; Battastini A.M.; Pohlmann A.R.; Guterres S.S.; Salbego C.; Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol [http:\/\/dx.doi.org\/10.1166\/jbn.2010.1161]2010,6(6),694-703","journal-title":"J Biomed Nanotechnol"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2009.03.021","volume":"375","author":"Lu X.","year":"2009","unstructured":"Lu X.; Ji C.; Xu H.; Li X.; Ding H.; Ye M.; Zhu Z.; Ding D.; Jiang X.; Ding X.; Guo X.; Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2009.03.021]2009,375(1-2),89-96","journal-title":"Int J Pharm"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/157341309787314656","volume":"5","author":"Bondi M.L.","year":"2009","unstructured":"Bondi M.L.; Montana G.; Craparo E.F.; Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer\u2019s disease: preparation, characterization and cytotoxicity studies. Curr Nanosci [http:\/\/dx.doi.org\/10.2174\/157341309787314656].2009,5(1),26-32","journal-title":"Curr Nanosci"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00204-012-0858-7","volume":"86","author":"Landsiedel R.","year":"2012","unstructured":"Landsiedel R.; Fabian E.; Ma-Hock L.; van Ravenzwaay B.; Wohlleben W.; Wiench K.; Oesch F.; Toxico-\/biokinetics of nanomaterials. Arch Toxicol [http:\/\/dx.doi.org\/10.1007\/s00204-012-0858-7]2012,86(7),1021-1060","journal-title":"Arch Toxicol"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/toxsci\/kfj027","volume":"89","author":"Kim J.S.","year":"2006","unstructured":"Kim J.S.; Yoon T.J.; Yu K.N.; Kim B.G.; Park S.J.; Kim H.W.; Lee K.H.; Park S.B.; Lee J.K.; Cho M.H.; Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci [http:\/\/dx.doi.org\/10.1093\/toxsci\/kfj027]2006,89(1),338-347","journal-title":"Toxicol Sci"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1289\/ehp.9209","volume":"114","author":"Kashiwada S.","year":"2006","unstructured":"Kashiwada S.; Distribution of nanoparticles in the see-through medaka (Oryzias latipes). Environ Health Perspect [http:\/\/dx.doi.org\/10.1289\/ehp.9209]2006,114(11),1697-1702","journal-title":"Environ Health Perspect"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.biomaterials.2015.06.041","volume":"65","author":"Li W.","year":"2015","unstructured":"Li W.; Luo R.; Lin X.; Jadhav A.D.; Zhang Z.; Yan L.; Chan C.Y.; Chen X.; He J.; Chen C.H.; Shi P.; Remote modulation of neural activities via near-infrared triggered release of biomolecules. Biomaterials [http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2015.06.041]2015,65,76-85","journal-title":"Biomaterials"},{"key":"ref=147","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/238428","volume":"2013","author":"Masserini M.","year":"2013","unstructured":"Masserini M.; Nanoparticles for brain drug delivery. ISRN Biochem [http:\/\/dx.doi.org\/10.1155\/2013\/238428]2013,2013","journal-title":"ISRN Biochem"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/smll.201201463","volume":"9","author":"Pietroiusti A.","year":"2013","unstructured":"Pietroiusti A.; Campagnolo L.; Fadeel B.; Interactions of engineered nanoparticles with organs protected by internal biological barriers. Small [http:\/\/dx.doi.org\/10.1002\/smll.201201463]2013,9(9-10),1557-1572","journal-title":"Small"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","volume":"12","author":"Martin L.","year":"2013","unstructured":"Martin L.; Latypova X.; Wilson C.M.; Magnaudeix A.; Perrin M.L.; Yardin C.; Terro F.; Tau protein kinases: involvement in Alzheimer\u2019s disease. Ageing Res Rev [http:\/\/dx.doi.org\/10.1016\/j.arr.2012.06.003]2013,12(1),289-309","journal-title":"Ageing Res Rev"},{"key":"ref=150","author":"Report W.A.","year":"2018","unstructured":"Report W.A.; World Alzheimer Report The state of the art of dementia research: New frontiers London: Alzheimer\u2019s Disease International 2018","journal-title":"World Alzheimer Report The state of the art of dementia research: New frontiers London: Alzheimer\u2019s Disease International"},{"key":"ref=151","first-page":"18","volume":"2","author":"Khemariya R.P.","year":"2016","unstructured":"Khemariya R.P.; Khemariya P.S.; New-tangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation. IJRMS 2016,2(2),18-29","journal-title":"IJRMS"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"12076","DOI":"10.1039\/C5NR03474D","volume":"7","author":"Fornaguera C.","year":"2015","unstructured":"Fornaguera C.; Feiner-Gracia N.; Calder\u00f3 G.; Garc\u00eda-Celma M.J.; Solans C.; Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale [http:\/\/dx.doi.org\/10.1039\/C5NR03474D]2015,7(28),12076-12084","journal-title":"Nanoscale"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","volume":"40","author":"Md S.","year":"2014","unstructured":"Md S.; Ali M.; Baboota S.; Sahni J.K.; Bhatnagar A.; Ali J.; Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm [http:\/\/dx.doi.org\/10.3109\/03639045.2012.758130]2014,40(2),278-287","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","volume":"124","author":"Baysal I.","year":"2017","unstructured":"Baysal I.; Ucar G.; Gultekinoglu M.; Ulubayram K.; Yabanoglu-Ciftci S.; Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm (Vienna) [http:\/\/dx.doi.org\/10.1007\/s00702-016-1527-4]2017,124(1),33-45","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1007\/s11095-008-9688-y","volume":"25","author":"Agyare E.K.","year":"2008","unstructured":"Agyare E.K.; Curran G.L.; Ramakrishnan M.; Yu C.C.; Poduslo J.F.; Kandimalla K.K.; Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer\u2019s disease and cerebral amyloid angiopathy. Pharm Res [http:\/\/dx.doi.org\/10.1007\/s11095-008-9688-y]2008,25(11),2674-2684","journal-title":"Pharm Res"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.colsurfb.2010.07.011","volume":"81","author":"Majzik A.","year":"2010","unstructured":"Majzik A.; F\u00fcl\u00f6p L.; Csap\u00f3 E.; Bog\u00e1r F.; Martinek T.; Penke B.; B\u00edr\u00f3 G.; D\u00e9k\u00e1ny I.; Functionalization of gold nanoparticles with amino acid, beta-amyloid peptides and fragment. Colloids Surf B Biointerfaces [http:\/\/dx.doi.org\/10.1016\/j.colsurfb.2010.07.011]2010,81(1),235-241","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","volume":"31","author":"Wang Z.H.","year":"2010","unstructured":"Wang Z.H.; Wang Z.Y.; Sun C.S.; Wang C.Y.; Jiang T.Y.; Wang S.L.; Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials [http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2009.09.104]2010,31(5),908-915","journal-title":"Biomaterials"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S171490","volume":"13","author":"Silva-Abreu M.","year":"2018","unstructured":"Silva-Abreu M.; Calpena A.C.; Andr\u00e9s-Benito P.; Aso E.; Romero I.A.; Roig-Carles D.; Gromnicova R.; Espina M.; Ferrer I.; Garc\u00eda M.L.; Male D.; PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer\u2019s disease: in vitro and in vivo studies. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S171490]2018,13,5577-5590","journal-title":"Int J Nanomedicine"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","volume":"461","author":"Zhang C.","year":"2014","unstructured":"Zhang C.; Chen J.; Feng C.; Shao X.; Liu Q.; Zhang Q.; Pang Z.; Jiang X.; Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2013.11.049]2014,461(1-2),192-202","journal-title":"Int J Pharm"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","volume":"17","author":"Kurakhmaeva K.B.","year":"2009","unstructured":"Kurakhmaeva K.B.; Djindjikhashvili I.A.; Petrov V.E.; Balabanyan V.U.; Voronina T.A.; Trofimov S.S.; Kreuter J.; Gelperina S.; Begley D.; Alyautdin R.N.; Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target [http:\/\/dx.doi.org\/10.1080\/10611860903112842]2009,17(8),564-574","journal-title":"J Drug Target"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/bc400055h","volume":"24","author":"Liu Z.","year":"2013","unstructured":"Liu Z.; Gao X.; Kang T.; Jiang M.; Miao D.; Gu G.; Hu Q.; Song Q.; Yao L.; Tu Y.; Chen H.; Jiang X.; Chen J.; B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug Chem [http:\/\/dx.doi.org\/10.1021\/bc400055h]2013,24(6),997-1007","journal-title":"Bioconjug Chem"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2004.11.003","volume":"289","author":"Schaffazick S.R.","year":"2005","unstructured":"Schaffazick S.R.; Pohlmann A.R.; de Cordova C.A.; Creczynski-Pasa T.B.; Guterres S.S.; Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2004.11.003]2005,289(1-2),209-213","journal-title":"Int J Pharm"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijpharm.2006.10.025","volume":"334","author":"He W.","year":"2007","unstructured":"He W.; Horn S.W.; Hussain M.D.; Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2006.10.025]2007,334(1-2),173-178","journal-title":"Int J Pharm"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bcp.2009.09.003","volume":"79","author":"Anand P.","year":"2010","unstructured":"Anand P.; Nair H.B.; Sung B.; Kunnumakkara A.B.; Yadav V.R.; Tekmal R.R.; Aggarwal B.B.; Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol [http:\/\/dx.doi.org\/10.1016\/j.bcp.2009.09.003]2010,79(3),330-338","journal-title":"Biochem Pharmacol"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/mp900306x","volume":"7","author":"Mulik R.S.","year":"2010","unstructured":"Mulik R.S.; M\u00f6nkk\u00f6nen J.; Juvonen R.O.; Mahadik K.R.; Paradkar A.R.; ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm [http:\/\/dx.doi.org\/10.1021\/mp900306x]2010,7(3),815-825","journal-title":"Mol Pharm"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejps.2010.06.010","volume":"41","author":"Dube A.","year":"2010","unstructured":"Dube A.; Nicolazzo J.A.; Larson I.; Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci [http:\/\/dx.doi.org\/10.1016\/j.ejps.2010.06.010]2010,41(2),219-225","journal-title":"Eur J Pharm Sci"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/jps.24557","volume":"104","author":"Elnaggar Y.S.","year":"2015","unstructured":"Elnaggar Y.S.; Etman S.M.; Abdelmonsif D.A.; Abdallah O.Y.; Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci [http:\/\/dx.doi.org\/10.1002\/jps.24557]2015,104(10),3544-3556","journal-title":"J Pharm Sci"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2009.03.064","volume":"455","author":"Liu G.","year":"2009","unstructured":"Liu G.; Men P.; Kudo W.; Perry G.; Smith M.A.; Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett [http:\/\/dx.doi.org\/10.1016\/j.neulet.2009.03.064]2009,455(3),187-190","journal-title":"Neurosci Lett"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","volume":"59","author":"Cui Z.","year":"2005","unstructured":"Cui Z.; Lockman P.R.; Atwood C.S.; Hsu C.H.; Gupte A.; Allen D.D.; Mumper R.J.; Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases. Eur J Pharm Biopharm [http:\/\/dx.doi.org\/10.1016\/j.ejpb.2004.07.009]2005,59(2),263-272","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"Misra S.","year":"2016","unstructured":"Misra S.; Chopra K.; Sinha V.R.; Medhi B.; Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv [http:\/\/dx.doi.org\/10.3109\/10717544.2015.1089956]2016,23(4),1434-1443","journal-title":"Drug Deliv"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","volume":"78","author":"Shah B.","year":"2015","unstructured":"Shah B.; Khunt D.; Bhatt H.; Misra M.; Padh H.; Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters. Eur J Pharm Sci [http:\/\/dx.doi.org\/10.1016\/j.ejps.2015.07.002]2015,78,54-66","journal-title":"Eur J Pharm Sci"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10715760903214454","volume":"43","author":"Picone P.","year":"2009","unstructured":"Picone P.; Bondi M.L.; Montana G.; Bruno A.; Pitarresi G.; Giammona G.; Di Carlo M.; Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res [http:\/\/dx.doi.org\/10.1080\/10715760903214454]2009,43(11),1133-1145","journal-title":"Free Radic Res"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","volume":"389","author":"Smith A.","year":"2010","unstructured":"Smith A.; Giunta B.; Bickford P.C.; Fountain M.; Tan J.; Shytle R.D.; Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer\u2019s disease. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2010.01.012]2010,389(1-2),207-212","journal-title":"Int J Pharm"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.msec.2017.03.303","volume":"77","author":"Kuo Y.C.","year":"2017","unstructured":"Kuo Y.C.; Rajesh R.; Nerve growth factor-loaded heparinized cationic solid lipid nanoparticles for regulating membrane charge of induced pluripotent stem cells during differentiation. Mater Sci Eng C [http:\/\/dx.doi.org\/10.1016\/j.msec.2017.03.303]2017,77,680-689","journal-title":"Mater Sci Eng C"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"Li W.","year":"2012","unstructured":"Li W.; Zhou Y.; Zhao N.; Hao B.; Wang X.; Kong P.; Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol [http:\/\/dx.doi.org\/10.1016\/j.etap.2012.04.012]2012,34(2),272-279","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","volume":"452","author":"Yang Z.Z.","year":"2013","unstructured":"Yang Z.Z.; Zhang Y.Q.; Wang Z.Z.; Wu K.; Lou J.N.; Qi X.R.; Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2013.05.009]2013,452(1-2),344-354","journal-title":"Int J Pharm"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/03639045.2010.541262","volume":"37","author":"Mutlu N.B.","year":"2011","unstructured":"Mutlu N.B.; De\u011fim Z.; Yilmaz \u015e.; E\u015fsiz D.; Nacar A.; New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm [http:\/\/dx.doi.org\/10.3109\/03639045.2010.541262]2011,37(7),775-789","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","volume":"58","author":"Arumugam K.","year":"2008","unstructured":"Arumugam K.; Subramanian G.S.; Mallayasamy S.R.; Averineni R.K.; Reddy M.S.; Udupa N.; A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm [http:\/\/dx.doi.org\/10.2478\/v10007-008-0014-3]2008,58(3),287-297","journal-title":"Acta Pharm"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DDDT.S113171","volume":"10","author":"Al Asmari A.K.","year":"2016","unstructured":"Al Asmari A.K.; Ullah Z.; Tariq M.; Fatani A.; Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016,10,205-215","journal-title":"Drug Des Devel Ther"},{"key":"ref=180","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/469679","volume":"2011","author":"Spuch C.","year":"2011","unstructured":"Spuch C.; Navarro C.; Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer\u2019s disease and Parkinson\u2019s disease). J Drug Deliv [http:\/\/dx.doi.org\/10.1155\/2011\/469679]2011,2011","journal-title":"J Drug Deliv"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biomaterials.2010.10.027","volume":"32","author":"Mourtas S.","year":"2011","unstructured":"Mourtas S.; Canovi M.; Zona C.; Aurilia D.; Niarakis A.; La Ferla B.; Salmona M.; Nicotra F.; Gobbi M.; Antimisiaris S.G.; Curcumin-decorated nanoliposomes with very high affinity for amyloid-\u03b21-42 peptide. Biomaterials [http:\/\/dx.doi.org\/10.1016\/j.biomaterials.2010.10.027]2011,32(6),1635-1645","journal-title":"Biomaterials"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2013.02.014","volume":"446","author":"Patel P.A.","year":"2013","unstructured":"Patel P.A.; Patil S.C.; Kalaria D.R.; Kalia Y.N.; Patravale V.B.; Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2013.02.014]2013,446(1-2),16-23","journal-title":"Int J Pharm"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/IJN.S37984","volume":"8","author":"Jin Y.","year":"2013","unstructured":"Jin Y.; Wen J.; Garg S.; Liu D.; Zhou Y.; Teng L.; Zhang W.; Development of a novel niosomal system for oral delivery of Ginkgo biloba extract. Int J Nanomedicine [http:\/\/dx.doi.org\/10.2147\/IJN.S37984]2013,8,421-430","journal-title":"Int J Nanomedicine"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2013.05.005","volume":"452","author":"Chaiyana W.","year":"2013","unstructured":"Chaiyana W.; Rades T.; Okonogi S.; Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricata. Int J Pharm [http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2013.05.005]2013,452(1-2),201-210","journal-title":"Int J Pharm"},{"key":"ref=185","first-page":"86","volume":"45","author":"Zhang L.K.","year":"2014","unstructured":"Zhang L.K.; Xu R.X.; Jiang M.; Evaluation of brain-targeting of \u03b2-asarone microemulsion by intranasal administration. Chin Tradit Herbal Drugs 2014,45(1),86-89","journal-title":"Chin Tradit Herbal Drugs"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/176794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T08:28:10Z","timestamp":1612427290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/176794\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":185,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666191118123151","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}